If you are interested in studying for a PhD in this research subject area click here 

For more details about the research topics, expertise and interests of this academic, click on the fingerprint icon

44 from 5,926 citations 

Last updated 24th March 2023

Professor Roger Phillips was appointed Professor of Cancer Pharmacology in July 2014.

Following a BSc in Marine Biology and Biochemistry (Joint Honours) from University College of North Wales, Bangor, Roger specialised in Cancer Pharmacology gaining his PhD in 1988 from the University of Bradford (under Profs John Double and Mike Bibby). After an initial postdoctoral position in Bradford, he moved to the School of Pharmacy, University of Southern California, Los Angeles to work with Dr Neil Gibson in 1991. He returned to Bradford in 1993 and secured academic appointments as lecturer (1996 to 2001), Senior Lecturer (2001 to 2003) and Reader (2003 to 1014) in Cancer Pharmacology. In July 2014, Roger was appointed as Professor of Cancer Pharmacology at the University of Huddersfield. He was also appointed as Director of Research in the School of Applied Sciences in August 2015.

His research focuses on the preclinical and early clinical evaluation of novel anti-cancer drugs with a specific interest in the tumour microenvironment as a target for drug development. His research has had clinical impact through the development of EO9 as a therapeutic drug for the treatment of superficial bladder cancer. He has published extensively in internationally recognised journals, has successfully supervised over 20 PhD students and continues to present his work at national and international conferences. He is a committee member of the European Organisation for the Research and Treatment of Cancer (EORTC) Drug Development Committee and the Pharmacology and Molecular Mechanism Group. He is also an editorial board member for the British Journal of Pharmacology.